Orthofix reported net sales of $111.7 million during the third quarter.
Here are five things to know:
1. Orthofix net sales increased 6.1 percent over the same period last year.
2. The company reported net loss of $1.2 million, down from the net income of $3.3 million in the third quarter of last year. The net loss was primarily driven by charges associated with Orthofix's acquisition of Spinal Kinetics and an unrealized loss on investment securities recognized during the quarter.
3. Net sales for the bone growth therapies line hit $48 million, an 8.1 percent increase over the same period last year, while the biologics net sales dropped 3.8 percent to $14.6 million. Spinal implants net sales hit $22.1 million, a 9.7 percent increase from Q3 of 2017.
4. EBITDA was reported as $3.6 million for the quarter, compared to $14.5 million last year. Cash and cash equivalents hit $56.2 million. The company does not have outstanding indebtedness as of the end of the quarter.
5. Orthofix projects full-year net sales will reach $450 million to $456 million in 2018, representing a 4 percent to 4.9 percent increase from 2017.